We are live on ! Find out more
CTNM

Contineum Therapeutics

90 hedge funds and large institutions have $399M invested in Contineum Therapeutics in 2026 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 29 increasing their positions, 21 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 11

38% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 21

18% more capital invested

Capital invested by funds: $338M → $399M (+$60.7M)

13% more funds holding

Funds holding: 8090 (+10)

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

34.64% less ownership

Funds ownership: 128.15%93.52% (-35%)

Holders
90
Holders Change
+10
Holders Change %
+12.5%
% of All Funds
1.11%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
22
Increased
29
Reduced
21
Closed
11
Calls
$148K
Puts
Net Calls
+$148K
Net Calls Change
+$191K
Name Holding Trade Value Shares
Change
Change in
Stake
Group One Trading
101
Group One Trading
Illinois
-$1.18K -103 Closed

CTNM Hedge Fund Activity: Q1 2026 in Review

90 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Contineum Therapeutics (CTNM) for Q1 2026, worth a combined $399M — up 18% from $338M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new CTNM positions and 11 closed out — a net gain of 11 holders — while 29 added to existing stakes and 21 trimmed.

The largest buyer was Millennium Management, adding an estimated $9.45M. The largest seller was RA Capital Management, cutting an estimated $11.9M.

  • 90 institutional investors held Contineum Therapeutics (CTNM) as of Q1 2026, up from 80 in Q4 2025.
  • Funds reported $399M of Contineum Therapeutics stock for Q1 2026, up 18% quarter-over-quarter.
  • 22 funds opened new Contineum Therapeutics positions in Q1 2026 and 11 closed out, a net change of +11 holders.
  • The largest Contineum Therapeutics buyer in Q1 2026 was Millennium Management, an estimated $9.45M added.
  • The largest Contineum Therapeutics seller in Q1 2026 was RA Capital Management, an estimated $11.9M sold.

Based on aggregated 13F filings for Q1 2026.